Alternative Incentive Models Delinking R&D Costs from Pharmaceutical Product Price

Abstract

The current incentive model based on the patent system is a failure in promoting pharmaceutical R&D addressing developing country health needs. It also blocks follow-on research and access to new pharmaceutical products to the impoverished lot, especially belonging to the developing countries. Thus it has become essential to think of an alternative incentive models delinking product price from the cost of R&D. An open access, collaborative research model, with prize fund incentive delinking costs of R&D from product price may be the appropriate incentive model for pharmaceutical R&D.<span style="mso-fareast-font-family: Calibri;mso-ansi-language:EN-US" lang="EN-GB"> It is also necessary to shift pharmaceutical R&D related issues from the trade fora to the human rights forum.

</span>